Back to top

Analyst Blog

Recently, Medtronic (MDT - Analyst Report) debriefed analysts about its ongoing performance in various divisions and markets during the Barclays Global Healthcare Conference. Below are the excerpts from the confab.

The European market dragged the performance of the company in the past few quarters. The company witnessed softness in the European market in the last quarter as well. However, the performance in the region is gradually improving. Additionally, Medtronic is planning to gain reimbursement for its offerings in many European nations. This should boost performance in the region.

With the Implantable Cardioverter Defibrillator (ICD) and Spine divisions in the U.S. representing one-third of the company’s business, the sluggish U.S. market for ICDs and Spine (which declined high single-digits to double-digits in last few quarters) hampered the performance of Medtronic and hurt growth in the last two years. Growth in other franchises also could not offset this adverse impact. However, management witnessed signs of stability in the domestic ICD and Spine market. Further, Medtronic is also gaining market share in ICD and Spine. However, pricing pressure prevails for the company.

According to management, the CRM (Cardiac Rhythm Management) market will grow in single-digits. While the company is capturing market share in Cardiac Rhythm Disease Management (CRDM) division on the back of newer products, it is gaining share in cardiovascular space with the recent launch of its Resolute Integrity in the U.S. as well as Japan.

The company continues to record 20% growth in the emerging markets, accounting for half of its overall growth. The adoption of its ICDs and pacers in the emerging market continues to improve. Moreover, commercialization of new products should accelerate growth in the emerging markets.

After acquiring China Kanghui Holdings, which will likely add strength to its orthopedic franchise in that country, Medtronic is keeping an eye on accretive buyouts in the region. This should expand Medtronic’s foothold in the emerging markets as it plans to achieve 20% of its revenues from emerging markets by fiscal 2015−16.

Medtronic expects revenue growth towards the higher end of the expected growth rate of 3%-4% for top line. The company also expects to record earnings per share towards the high end of the outlook band of $3.66 and $3.70 for fiscal 2013. Medtronic is slated to release fourth-quarter results on May 21, 2013.

The stock carries a Zacks Rank #3 (Hold). While we remain on the sidelines for this medical device major, other medical stocks that warrant a look are Abaxis (ABAX - Analyst Report), Conceptus and Edwards Lifesciences (EW - Analyst Report). These stocks carry a Zacks Rank #2 (Buy).

Please login to or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research


Are you a new Zacks Member or a visitor to

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
CENTURY ALU… CENX 22.53 +4.50%
ERBA DIAGNO… ERB 2.91 +4.30%
PLANAR SYST… PLNR 4.31 +3.86%
MALLINCKROD… MNK 72.17 +3.83%
GTT COMMUNI… GTT 12.06 +3.52%